A Randomized, Double-Blind Phase 3 Trial of Maintenance Therapy With Niraparib vs Placebo in Patients With Platinum-Sensitive Recurrent Ovarian Cancer (ENGOT-OV16/NOVA Trial)

被引:0
|
作者
不详
机构
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Improving the response rate to neoadjuvant chemotherapy by adding antiangiogenic therapy could increase the rate of complete resection at interval debulking surgery. However, the use of bevacizumab raises concerns regarding wound healing. The phase 2 CHIVA study (Vargatef in Addition to First Line Chemotherapy With Interval De bulking Surgery in Patients With Ovarian Cancer) evaluated the safety and effcacy of nintedanib, an oral antiangiogenic tyrosine kinase inhibitor with a short half-life (Abstract 859PD). The trial enrolled patients with International Federation of Gynecology and Obstetrics stage IIIC to IV cancer of the ovary, fallopian tube, or primary peritoneum. Patients were randomized 2: 1 to receive nintedanib or placebo in addition to chemotherapy before and after interval debulking surgery. All patients received 3 cycles of neoadjuvant chemotherapy before interval debulking surgery and 3 cycles of chemotherapy after. There were 72 patients in the nintedanib arm and 49 in the placebo arm. The majority of patients had serous/papillary disease of histologic grade 3. The rates of complications during surgery were 13% in patients receiving nintedanib vs 18% in those receiving placebo. The addition of nintedanib to neoadjuvant chemotherapy did not increase the rate of postoperative complications. In the placebo vs nintedanib cohorts, rates of grade 1/2 AEs were 52% vs 54%, respectively, and rates of grade 3/4 AEs were 18% vs 13%.
引用
收藏
页码:3 / 5
页数:3
相关论文
共 50 条
  • [21] Fuzuloparib maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer: a multicenter, randomized, double-blind, placebo-controlled, phase III trial
    Li, Ning
    Zhang, Youzhong
    Wang, Jing
    Zhu, Jianqing
    Wang, Li
    Wu, Xiaohua
    Yao, Desheng
    Wu, Qiang
    Liu, Jihong
    Tang, Junying
    Yin, Rutie
    Zhang, Guonan
    Lou, Ge
    An, Ruifang
    Xia, Xiaoping
    Li, Qingshui
    Zhu, Yaping
    Hong, Zheng
    Yang, Xinfeng
    Hu, Yuanjing
    Zhang, Xin
    Wan, Xiaoyun
    Qu, Jing
    Zhang, Ben
    Wu, Lingying
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S57 - S58
  • [22] Individualized starting dose of niraparib in Chinese patients with platinum-sensitive recurrent ovarian cancer (PSROC): A randomized, double-blind, placebo-controlled, phase III trial (NORA)
    Wu, X.
    Zhu, J.
    Yin, R.
    Yang, J.
    Liu, J.
    Wang, J.
    Wu, L.
    Liu, Z.
    Gao, Y.
    Wang, D.
    Lou, G.
    Yang, H.
    Zhou, Q.
    Kong, B.
    Huang, Y.
    Chen, L.
    Li, G.
    An, R.
    Wang, K.
    Zhang, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S1160 - S1161
  • [24] Safety assessment of niraparib individualized starting dose in patients with platinum-sensitive recurrent ovarian cancer: A randomized, double-blind, placebo-controlled, phase III NORA trial.
    Wang, Jing
    Wu, Xiaohua
    Zhu, Jianqing
    Yin, Rutie
    Yang, Jiaxin
    Huang, Qidan
    Wu, Lingying
    Liu, Ziling
    Gao, Yunong
    Wang, Danbo
    Lou, Ge
    Yang, Hongying
    Zhou, Qi
    Kong, Beihua
    Huang, Yi
    Chen, Lipai
    Li, Guiling
    An, Ruifang
    Tan, Tao
    Dong, Juan
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [25] Niraparib maintenance therapy using an individualised starting dose in patients with platinum-sensitive recurrent ovarian cancer (NORA): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 trial
    Wu, Xiaohua
    Zhu, Jianqing
    Yin, Rutie
    Yang, Jiaxin
    Liu, Jihong
    Wang, Jing
    Wu, Lingying
    Liu, Ziling
    Gao, Yunong
    Wang, Danbo
    Lou, Ge
    Yang, Hongying
    Zhou, Qi
    Kong, Beihua
    Huang, Yi
    Huang, Zhao
    Dong, Juan
    Zhang, Charlie
    Hou, Jianmei
    Mirza, Mansoor R.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A287 - A287
  • [26] Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial
    Li, Ning
    Zhang, Youzhong
    Wang, Jing
    Zhu, Jianqing
    Wang, Li
    Wu, Xiaohua
    Yao, Desheng
    Wu, Qiang
    Liu, Jihong
    Tang, Junying
    Yin, Rutie
    Lou, Ge
    An, Ruifang
    Zhang, Guonan
    Xia, Xiaoping
    Li, Qingshui
    Zhu, Yaping
    Zheng, Hong
    Yang, Xinfeng
    Hu, Yuanjing
    Zhang, Xin
    Hao, Min
    Huang, Yi
    Lin, Zhongqiu
    Wang, Dong
    Guo, Xiaoqing
    Yao, Shuzhong
    Wan, Xiaoyun
    Zhou, Huaijun
    Yao, Liangqing
    Yang, Xielan
    Cui, Heng
    Meng, Yuanguang
    Zhang, Songling
    Qu, Jing
    Zhang, Ben
    Zou, Jianjun
    Wu, Lingying
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (22) : 2436 - +
  • [27] Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial
    Matulonis, Ursula A.
    Walder, Lydia
    Nottrup, Trine J.
    Bessette, Paul
    Mahner, Sven
    Gil-Martin, Marta
    Kalbacher, Elsa
    Ledermann, Jonathan A.
    Wenham, Robert M.
    Woie, Kathrine
    Lau, Susie
    Marme, Frederik
    Casado Herraez, Antonio
    Hardy-Bessard, Anne-Claire
    Banerjee, Susana
    Lindahl, Gabriel
    Benigno, Benedict
    Buscema, Joseph
    Travers, Karin
    Guy, Holly
    Mirza, Mansoor R.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (34) : 3183 - 3191
  • [28] Safety and dose modification for patients with low body weight receiving niraparib in the ENGOT-OV16/NOVA phase III trial
    Lord, R.
    Mirza, M. R.
    Woelber, L.
    Lesoin, A.
    Pineda, M. J.
    Peen, U.
    Hazard, S. J.
    Matulonis, U. A.
    GYNECOLOGIC ONCOLOGY, 2018, 149 : 11 - 11
  • [29] Efficacy and safety of niraparib in Chinese patients with platinum-sensitive recurrent ovarian cancer (NORA) with individualized starting dose: A subgroup analysis of a randomized, double-blind, placebo-controlled, phase III trial
    Wu, X.
    Zhu, J.
    Yin, R.
    Yang, J.
    Liu, J.
    Wang, J.
    Wu, L.
    Liu, Z.
    Gao, Y.
    Wang, D.
    Lou, G.
    Yang, H.
    Zhou, Q.
    Kong, B.
    Huang, Y.
    Chen, L.
    Li, G.
    An, R.
    Wang, K.
    Zhang, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S1335 - S1335
  • [30] Time without symptoms or toxicity in patients with recurrent ovarian cancer receiving niraparib maintenance treatment versus placebo: A TWIST analysis of the ENGOT24-OV16/NOVA trial
    Matulonis, U. A.
    Walder, L.
    Nottrup, T. J.
    Tinker, A. V.
    Mahner, S.
    Gil-Martin, M.
    Fabbro, M.
    Banerjee, S.
    Wenham, R. M.
    Woie, K.
    Gilbert, L.
    Harter, P.
    Casado Herraez, A.
    Follana, P.
    Ledermann, J. A.
    Leroy, C.
    Scollo, P.
    Lund, B.
    Malander, S.
    Fisher, M.
    Guy, H.
    Mirza, M. R.
    GYNECOLOGIC ONCOLOGY, 2019, 154 : 2 - 2